3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
7
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Nasopharyngeal Carcinoma
7
Breast Neoplasms
6
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Neoplasm Metastasis
2
Locally Advanced Rectal Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Adrenocortical Carcinoma
2
Unresectable Gallbladder Cancer
1
Turcot syndrome
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Non Squamous Non Small Cell Lung Cancer
1
Nasopharyngeal Neoplasms
1
Multiple Primary Lung Cancer
1
Melanoma
1
Locally Advanced or Metastatic Solid Tumors
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Her-2 Negative Breast Cancer
1
Interventions
Doxorubicin
15
pembrolizumab
12
Surgical Procedures, Operative
8
Cyclophosphamide
8
Blood Specimen Collection
8
Ifosfamide
7
Gemcitabine
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
atezolizumab
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
pazopanib
3
liposomal doxorubicin
3
fludarabine
3
cabozantinib
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
camrelizumab
×
Clear all
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled